ArticleNanomedicine (London, England)2025
Innate immuno-response to nanoparticle uptake in liver and spleen mimics pathogen infection.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Targeted Nanoparticle Delivery CRISPR/Cas9: overcoming biological barriers, enhancing stability, and improving therapeutic precision.International journal of pharmaceutics: X · 2026Review
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Systematic discovery of immunomodulatory plant-derived nanoparticles reveals RNA-mediated macrophage reprogramming.Bioactive materials · 2026Article
- Antioxidant Polymeric and Non-Polymeric Nanoformulations for the Treatment of Autoimmune Diseases.Current issues in molecular biology · 2026Review
- Core-Shell Plasmonic Nanocomposites with Synergistic Photothermal and Photochemical Activity for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection.Extracellular vesicles and circulating nucleic acids · 2026Article
- Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.International journal of nanomedicine · 2026Review
- Therapeutic Targets, Pharmacological Mechanisms, and Delivery Strategies for Diabetic Peripheral Neuropathy.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSystemically administered nanoparticles (NPs) designed for biomedical applications are retained in liver and spleen where they become rapidly phagocyted by tissue macrophages leading to inflammation.
methodsTo gain insight into the NP-immune cell interaction in liver spleen and lungs, we followed the distribution of molybdenum nanoparticles (MoNPs)
resultsXRF imaging showed that intravenously administered MoNPs transiently accumulate in lungs, liver, and spleen. This leads to increments in the number of Kupffer cells (KC), natural killer (NK) cells, oxidative stress, and inflammation. Macrophage phenotype switched from pro- to an anti-inflammatory. In parallel genes with immunoregulatory and cytoprotective functions were expressed to maintain homeostasis. Nanoparticle uptake in spleen was operated by CD169/Siglec1 splenic macrophages indicating initiation of a secondary immune response. Silica coating reduced nanoparticle toxicity.
conclusionThe innate immunoresponse to NP uptake in liver and spleen is similar to viral or bacterial infections in these organs. A possible secondary immunoresponse to NPs can be primed in spleen aided by CD169/Siglec1 splenic macrophages. Silica coating of metal NPs tunes down this response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.